Kaneva Erlotinib Ramucirumab
MinorNo clinically meaningful changes in the exposure of either Cyramza or its concomitant drugs in the approved combinations, including paclitaxel, docetaxel, irinotecan (or its active metabolite, SN-38), and erlotinib were observed in patients with solid tumors.
Little or no effect is expected. You usually do not need to change anything, but still tell your doctor or pharmacist about every medicine you take.